

Disclosures

Personal Commercial (25)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Aegerion	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Ainylam	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Amarin	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Amgen	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Amgen	Research/Research Grants ‡ <i>To Be Announced</i>	Significant (>= \$5,000)	<i>Prevention</i>
Applied Therapeutics	Data Safety Monitoring Board	Modest (< \$5,000)	<i>General Cardiology</i>
Ascendia	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Better Therapeutics	Research/Research Grants	Significant (>= \$5,000)	<i>Prevention</i>
BMS	Research/Research Grants ‡ <i>AEIOU trial</i>	Significant (>= \$5,000)	<i>Arrhythmias and Clinical EP</i>
BMS	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
Boehringer-Ingelheim	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>General Cardiology</i>
Boehringer-Ingelheim	Research/Research Grants ‡ <i>RE-DUAL PCI</i>	Significant (>= \$5,000)	<i>General Cardiology</i>
Daiichi Sankyo	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	<i>General Cardiology</i>
Lexicon	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Prevention</i>
Merck	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Merck	Research/Research Grants ‡ <i>IMPROVE IT, and REVEAL</i>	Significant (>= \$5,000)	<i>Prevention</i>
Novo Nordisk Inc.	Data Safety Monitoring Board	Significant (>= \$5,000)	<i>Prevention</i>
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	<i>Prevention</i>
Pfizer	Research/Research Grants	Significant (>= \$5,000)	<i>Prevention</i>
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>General Cardiology</i>
RhoShan	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes</i>
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Acute Coronary Syndromes Prevention</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/19/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/19/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/19/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 9/19/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.